The phase 2 trial NCT03444376 combining the HPV16/18-targeting DNA vaccine GX-188E with pembrolizumab reported a 35.0% ORR and a median OS of 23.8 months, displaying robust anti-tumor activity regardless of PD-L1 status [73]. This evidence concerns the gene CD274 and neoplasm.